中智药业将投资GABAeron 投资额300万美元
财中社12月23日电中智药业（03737）发布公告，宣布与美国生物医药公司GABAeron签署投资协议。根据协议，公司将以300万美元认购GABAeron的300万股A系列优先股，相当于GABAeron优先股约11.5%的持股权益。此次投资旨在推进GABAeron的GR01细胞移植治疗阿尔茨海默病（AD）的临床试验，为未来的Ⅱ、Ⅲ期临床试验奠定基础。
GABAeron专注于开发针对阿尔茨海默病的高科技创新疗法，利用人类诱导型多能干细胞治疗携带apoE4基因的老年痴呆患者，已通过FDA Pre-IND审核，即将进入临床一期研究。这一投资标志着公司在生物医药领域的战略布局迈向新台阶，预计将为全球AD患者带来新的治疗方案，改善其生活质量。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10